glp-1 reta Comment “Curious” for the deep dive. Retatrutide — a.k.a. “Reta” or “GLP-3” — is being called a future “trillion-dollar drug” and a revolution in fat loss. Retatrutide is a third-generation GLP-1–based drug. ( New GLP-1 obesity drug, retatrutide,

In the deal, Roche is adding CT-388, a Phase-2 ready, weekly-administered dual GLP-1/GIP receptor agonist for treating obesity in patients with and without type 2 diabetes

This is weight loss with heart, rooted in our Louisiana values

Cagrilintide 5mg + Semaglutide 5mg Strength: 10mg CAS: Cagrilintide: 1415456-99-3 Semaglutide: 910463-68-2 Chemical Formula: Cagrilintide: CHNOS Semaglutide: CHNO Molecular weight: Cagrilintide:4409 g/mol Semaglutide: 4114 g/mol Peptide Sequence: Cagrilintide: XKCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP Semaglutide: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc--Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-OH Synonyms: CagriSema Storage: Store 28 C (20 C long-term)

[6] In 2023, it was the 160th most commonly prescribed medication in the United States, with more than 3 million prescriptions

"It works by helping to stabilize blood clots and prevent their breakdown." Dr